Indu Rajagopal1, S R Niveditha2, R Sahadev3, Preethan Kamagere Nagappa4, Sowmya Goddanakoppal Rajendra5. 1. Post Graduate, Department of Pathology, Kempegowda Institute of Medical Sciences , Karnataka, India . 2. Professor, Department of Pathology, Kempegowda Institute of Medical Sciences , Karnataka, India . 3. Professor and HOD, Department of Surgical Gastroenterology, Kempegowda Institute of Medical Sciences , Karnataka, India . 4. Associate Professor, Department of Surgical Gastroenterology, Kempegowda Institute of Medical Sciences , Karnataka, India . 5. Senior Resident, Department of Surgical Gastroenterology, Kempegowda Institute of Medical Sciences , Karnataka, India .
Abstract
INTRODUCTION: Gastric cancer is one of the leading causes of cancer mortality in the world/India with majority being diagnosed at an advanced stage. Various chemotherapeutic regimens have modestly improved overall survival leading to quest for novel therapeutic agents. Overexpression of HER2 in many gastric cancers has lead to the advent of targeted therapy with anti HER2 antibody like Trastusumab which has improved the overall survival. MATERIALS AND METHODS: Sixty cases of gastric adenocarcinomas (44 biopsies and 16 gastrectomies) over the past five years ( June 2009 to June 2014),were included in the study. Diagnosis was confirmed by review of slides and IHC with anti HER2 antibodies was performed using Dako Real Envision Detection system and scoring was done by Hoffmann et al., scoring system. RESULTS: Of the 60 cases, majority were males (60%),with a mean age of 65.65 yrs. Tumours in antrum (76.7%) formed the major bulk. HER2 expression was observed in 26.7% of Tumours, predominantly in males (p=0.006) and intestinal type (p= 0.054). HER2 expression correlated with Tumour grade (moderately differentiated and well differentiated, p= 0.042). Tumours of gastro-esophageal junction (GEJ) showed HER2 expression in 45.5% as opposed to 22.4% in gastric location. Poorly differentiated and diffuse type of adenocarcinomas did not express HER2. Two of three Tumours from patients in the age group 31-40 y expressed HER2. CONCLUSION: Male gender, intestinal-type and moderately differentiated gastric cancers may be the ones that can be targeted for therapy using Herceptin. Though trastusumab is approved for advanced gastric and GEJ cancers, it's role in adjuvant / neo-adjuvant setting in early stages needs to be evaluated with newer agents like Pertuzumab, Bevacizumab, especially in young patients.
INTRODUCTION: Gastric cancer is one of the leading causes of cancer mortality in the world/India with majority being diagnosed at an advanced stage. Various chemotherapeutic regimens have modestly improved overall survival leading to quest for novel therapeutic agents. Overexpression of HER2 in many gastric cancers has lead to the advent of targeted therapy with anti HER2 antibody like Trastusumab which has improved the overall survival. MATERIALS AND METHODS: Sixty cases of gastric adenocarcinomas (44 biopsies and 16 gastrectomies) over the past five years ( June 2009 to June 2014),were included in the study. Diagnosis was confirmed by review of slides and IHC with anti HER2 antibodies was performed using Dako Real Envision Detection system and scoring was done by Hoffmann et al., scoring system. RESULTS: Of the 60 cases, majority were males (60%),with a mean age of 65.65 yrs. Tumours in antrum (76.7%) formed the major bulk. HER2 expression was observed in 26.7% of Tumours, predominantly in males (p=0.006) and intestinal type (p= 0.054). HER2 expression correlated with Tumour grade (moderately differentiated and well differentiated, p= 0.042). Tumours of gastro-esophageal junction (GEJ) showed HER2 expression in 45.5% as opposed to 22.4% in gastric location. Poorly differentiated and diffuse type of adenocarcinomas did not express HER2. Two of three Tumours from patients in the age group 31-40 y expressed HER2. CONCLUSION: Male gender, intestinal-type and moderately differentiated gastric cancers may be the ones that can be targeted for therapy using Herceptin. Though trastusumab is approved for advanced gastric and GEJ cancers, it's role in adjuvant / neo-adjuvant setting in early stages needs to be evaluated with newer agents like Pertuzumab, Bevacizumab, especially in young patients.
Entities:
Keywords:
Gastric / GEJ adenocarcinoma; HER2/ neu; Immunohistochemistry (IHC)
Authors: Laura J Tafe; Yelena Y Janjigian; Michael Zaidinski; Cyrus V Hedvat; Meera R Hameed; Laura H Tang; James B Hicks; Manish A Shah; Violetta Barbashina Journal: Arch Pathol Lab Med Date: 2011-11 Impact factor: 5.534
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Leandro Luongo de Matos; Damila Cristina Trufelli; Maria Graciela Luongo de Matos; Maria Aparecida da Silva Pinhal Journal: Biomark Insights Date: 2010-02-09
Authors: You-Lin Qiao; Sanford M Dawsey; Farin Kamangar; Jin-Hu Fan; Christian C Abnet; Xiu-Di Sun; Laura Lee Johnson; Mitchell H Gail; Zhi-Wei Dong; Binbing Yu; Steven D Mark; Philip R Taylor Journal: J Natl Cancer Inst Date: 2009-03-24 Impact factor: 13.506
Authors: Cathy B Moelans; Anya N Milne; Folkert H Morsink; G Johan A Offerhaus; Paul J van Diest Journal: Cell Oncol (Dordr) Date: 2011-03-11 Impact factor: 6.730
Authors: Shashikant C U Patne; V B Abhilash; Vinod Kumar Dixit; Richa Katiyar; Sandip Kumar; Gyan Prakash Singh Journal: J Clin Diagn Res Date: 2017-05-01
Authors: Ahmed Abdel Hadi; Ali El Hindawi; Amal Hareedy; Heba Khalil; Ranya Al Ashiry; Shady Elia; Ahmed Sadek; Mona Magdy; Rafatt Atta; Amgad Anas; Hisham Bakr; Olfat Hammam Journal: Open Access Maced J Med Sci Date: 2016-09-11